Internal Medicine, Endocrinology, Diabetes, & Metabolism · Southaven, MS
NPI
1538430244
Since 2012
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
4
Medicare group memberships
Hospitals
5
Hospital affiliations
401 Southcrest Cir Ste 202
Southaven, MS, 38671
Phone (901) 763-3636
Groups this clinician bills Medicare through
Medicare paid, 2024
$104K
3,591 services
Medicare patients, 2024
329
Average age 71
Drug cost, 2024
$5.0M
3,201 prescriptions
Company payments, 2025
$59K
From 23 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Delali O Blavo was code 82962 (clinical chemistry), 416 times for 167 patients. In total Delali O Blavo billed 3,591 services in 45 codes, and Medicare paid $104K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-06.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 82962 Clinical Chemistry | Office | 416 | 167 | $3.17 | $1,321 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 395 | 229 | $11.44 | $4,518 |
| 36415 Venipuncture Blood Collection | Office | 387 | 254 | $8.53 | $3,300 |
| 83036 Blood Count | Office | 374 | 167 | $9.47 | $3,541 |
| 99215 Office E&M - Established | Office | 363 | 180 | $118.32 | $43K |
| 84443 Clinical Chemistry | Office | 266 | 196 | $16.22 | $4,315 |
| 80053 Clinical Chemistry | Office | 245 | 185 | $10.25 | $2,510 |
| 99214 Office E&M - Established | Office | 243 | 152 | $79.07 | $19K |
| 95251 Test - Miscellaneous | Office | 151 | 65 | $24.36 | $3,679 |
| 84439 Clinical Chemistry | Office | 145 | 107 | $8.66 | $1,256 |
| 80061 Clinical Chemistry | Office | 117 | 98 | $13.05 | $1,526 |
| 82306 Clinical Chemistry | Office | 67 | 60 | $28.65 | $1,919 |
| 82570 Clinical Chemistry | Office | 64 | 62 | $5.08 | $325 |
| 82043 Clinical Chemistry | Office | 63 | 61 | $5.66 | $357 |
| 99421 Office/Outpatient Services | Office | 63 | 34 | $10.25 | $646 |
By year: 2022 $93K for 3,343 services; 2023 $93K for 2,959 services; 2024 $104K for 3,591 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 416 | 167 | $3.17 | $1,321 |
| 36415 Venipuncture Blood Collection | 387 | 254 | $8.53 | $3,300 |
| 83036 Blood Count | 374 | 167 | $9.47 | $3,541 |
| 84443 Clinical Chemistry | 266 | 196 | $16.22 | $4,315 |
| 80053 Clinical Chemistry | 245 | 185 | $10.25 | $2,510 |
| 84439 Clinical Chemistry | 145 | 107 | $8.66 | $1,256 |
| 80061 Clinical Chemistry | 117 | 98 | $13.05 | $1,526 |
| 82306 Clinical Chemistry | 67 | 60 | $28.65 | $1,919 |
| 82570 Clinical Chemistry | 64 | 62 | $5.08 | $325 |
| 82043 Clinical Chemistry | 63 | 61 | $5.66 | $357 |
Medicare prescription drug claims, 2024
In 2024, the drug Delali O Blavo prescribed most often to Medicare patients was Levothyroxine Sodium, with 219 prescriptions and refills. In total Delali O Blavo wrote 3,201 Medicare prescriptions that cost $5.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 219 | 524 | 63 | $1,585 |
| Ozempic Semaglutide | 214 | 309 | 53 | $276K |
| Metformin Hcl Generic | 149 | 393 | 42 | $759 |
| Korlym Mifepristone | 108 | 108 | 15 | $3.6M |
| Mounjaro Tirzepatide | 105 | 124 | 22 | $126K |
| Tresiba Flextouch U-200 Insulin Degludec | 95 | 212 | 34 | $123K |
| Farxiga Dapagliflozin Propanediol | 95 | 178 | 22 | $97K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 89 | 199 | 33 | $18K |
| Novolog Flexpen Insulin Aspart | 72 | 127 | 30 | $16K |
| Gabapentin Generic | 70 | 187 | 29 | $759 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 68 | 135 | 30 | $6,839 |
| Glimepiride Generic | 65 | 181 | 21 | $639 |
| Januvia Sitagliptin Phosphate | 61 | 113 | 11 | $61K |
| Rosuvastatin Calcium Generic | 58 | 164 | 22 | $699 |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 57 | 98 | 15 | $41K |
Brand drugs: 1,795 claims; generic drugs: 1,164 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Delali O Blavo $59K ($59K in general payments such as food, travel and fees) from 23 companies. The largest payer was Corcept Therapeutics with $46K.
| Company | Payments | Amount |
|---|---|---|
| Corcept Therapeutics CORT | 61 | $46K |
| Xeris Pharmaceuticals, Inc. | 30 | $6,448 |
| CeQur Corporation | 2 | $3,427 |
| Recordati_rare_diseases_inc. | 6 | $499 |
| Lilly USA, LLC LLY | 18 | $463 |
| Mannkind Corporation MNKD | 7 | $276 |
| Novo Nordisk Inc NVO | 13 | $261 |
| Ascendis Pharma Endocrinology Inc ASND | 4 | $205 |
| Medtronic, Inc. MDT | 6 | $178 |
| Amgen Inc. AMGN | 11 | $177 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.